Patents by Inventor Ralf Herwig

Ralf Herwig has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190134064
    Abstract: The invention relates to a dimeric complex of a selectively deglycosylated vitamin D-binding protein (GcMAF) and cholecalciferol (calciol). The invention further relates to a method for producing such a complex, wherein a vitamin D-binding protein is reacted with calciol and is selectively deglycosylated before or after being reacted. The resulting product is finally separated from impurities with a larger molecular weight, in particular enzymes of the selective deglycosylation process, using a molecular sieve with a cutoff value of more than 60 kDa.
    Type: Application
    Filed: April 21, 2017
    Publication date: May 9, 2019
    Inventors: Ralf HERWIG, Joachim GREILBERGER
  • Publication number: 20160108476
    Abstract: The invention relates to the identification and selection of novel genomic regions (biomarker) and the identification and selection of novel genomic region combinations which are hypermethylated in subjects with colorectal cancer compared to subjects without colorectal cancer. Nucleic acids which selectively hybridize to the genomic regions and products thereof are also encompassed within the scope of the invention as are compositions and kits containing said nucleic acids and nucleic acids for use in diagnosing prostate cancer. Further encompassed by the invention is the use of nucleic acids which selectively hybridize to one of the genomic regions or products thereof to monitor disease progression or regression in a patient and the efficacy of therapeutic regimens.
    Type: Application
    Filed: August 14, 2013
    Publication date: April 21, 2016
    Inventors: Michal-Ruth SCHWEIGER, Christina GRIMM, Ralf HERWIG, Hans LEHRACH
  • Publication number: 20160042119
    Abstract: The present invention relates to a computer-implemented method of producing a kinetic model of a biological network. An example method can comprise choosing a network topology. The nodes of said topology represent biological entities and the edges of said topology represent interactions between said entities. An example method can comprise assigning kinetic laws and kinetic constants to said interactions and assigning starting concentrations to said biological entities. One part of said kinetic constants and independently one part of said starting concentrations are experimental data. The remaining part of said kinetic constants and independently the remaining part of said starting concentrations are chosen randomly.
    Type: Application
    Filed: August 7, 2015
    Publication date: February 11, 2016
    Inventors: Hans Lehrach, Ralf Herwig, Christoph Wierling
  • Publication number: 20110191087
    Abstract: The present invention relates to a computer-implemented method of producing a kinetic model of a biological network, the method comprising (a) choosing a network topology, wherein the nodes of said topology represent biological entities and the edges of said topology represent interactions between said entities; (b) assigning kinetic laws and kinetic constants to said interactions; and (c) assigning starting concentrations to said biological entities, wherein (i) one part of said kinetic constants and independently one part of said starting concentrations are experimental data; and (ii) the remaining part of said kinetic constants and independently the remaining part of said starting concentrations are chosen randomly.
    Type: Application
    Filed: September 3, 2009
    Publication date: August 4, 2011
    Applicant: Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V.
    Inventors: Hans Lehrach, Ralf Herwig, Christoph Wierling
  • Patent number: 7855191
    Abstract: Disclosed is an agent which has a destructive effect on malignant tumors and contains alpha-ketoglutaric acid, N-acetyl-seleno-L-methionine, N-acetyl-L-methionine, and a compound that is capable of forming azomethine and is selected among the group 5-hydroxymethylfurfural, dehydroascorbic acid, maltol, and vanillin as an active substance, 5-hydroxymethylfurfural being preferred. The inventive agent can be used in the form of an infusion, in an oral or rectal form of administration, or as an irrigation in cancer therapy.
    Type: Grant
    Filed: October 13, 2003
    Date of Patent: December 21, 2010
    Assignees: C.Y.L. Pharmazeutika GmbH
    Inventors: Karl Groke, Ilse Groke, legal representative, Veronika Groke, legal representative, Paul Groke, legal representative, Ralf Herwig, Peter Ferdinand
  • Publication number: 20060292218
    Abstract: Disclosed is an agent which has a destructive effect on malignant tumors and contains alpha-ketoglutaric acid, N-acetyl-seleno-L-methionine, N-acetyl-L-methionine, and a compound that is capable of forming azomethine and is selected among the group 5-hydroxymethylfurfural, dehydroascorbic acid, maltol, and vanillin as an active substance, 5-hydroxymethylfurfural being preferred. The inventive agent can be used in the form of an infusion, in an oral or rectal form of administration, or as an irrigation in cancer therapy.
    Type: Application
    Filed: October 13, 2003
    Publication date: December 28, 2006
    Inventors: Karl Groke, Ilse Groke, Veronika Groke, Paul Groke, Ralf Herwig, Peter Ferdinand
  • Publication number: 20060094067
    Abstract: The invention relates to a method and an analysis arrangement for the determination of characteristics and/or classification of circulating macrophages. A whole blood sample is subjected to a gradient centrifugation for isolating macrophages. The macrophage cells are then perforated and provided with an intracellular staining with at least one selected antibody. A flow cytometric analysis of the pre-treated cells enables a subsequent statistical evaluation of the cell contents. PSA, a cytokeratin and/or an epithelial membrane antigen are selected as antibodies.
    Type: Application
    Filed: June 2, 2003
    Publication date: May 4, 2006
    Inventor: Ralf Herwig